logo

For the Inventor, By the Inventor

Cary, NC, United States of America

Dennis Michael Lambert

This inventor holds 24 USPTO granted patents and 1 published patent application, plus 3 CIPO patents, primarily in Viral Fusion Inhibition. Top assignees: Trimeris, Inc., Duke University, Other. Active years: 2000-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dennis Michael Lambert. Retrieved from https://idiyas.com/inventor/dennis-michael-lambert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 24 

% Patents Active = 79.2

 

Average Co-Inventor Count = 3.2

ph-index = 14

Forward Citations = 356(Granted Patents)


Location History:

  • Durham, NC (US) (2003)
  • Fair Oaks, CA (US) (2004)
  • Cary, NC (US) (2000 - 2010)

Company Filing History:

goldMedal21 out of 31 
 
Trimeris, Inc.
 patents
silverMedal2 out of 2,085 
 
Duke University
 patents
bronzeMedal2 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 2000-2010

Loading Chart...
Loading Chart...
Areas of Expertise:
HIV Treatment
Antiviral Compounds
Fusion Inhibitory Domains
Membrane Fusion
Peptide Therapy
Viral Infections
Pharmacokinetic Properties
Combinatorial Therapy
Respiratory Syncytial Virus
Epstein-Barr Virus
Simian Immunodeficiency Virus
Measles Virus
24 patents (USPTO):Explore Patents
1. 7794725 - Isolated peptides derived from human immunodeficiency virus types 1 and 2 containing fusion inhibitory domains (2010-09-14),
2. 7514397 - Methods for inhibition of membrane-fusion-associated events, including Hepatitis B virus transmission (2009-04-07),
3. 7297784 - DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids (2007-11-20),
4. 7122190 - Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids (2006-10-17),
5. 6951717 - Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission (2005-10-04),
6. 6861059 - Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations (2005-03-01),
7. 6811541 - Traction device (2004-11-02),
8. 6656906 - Hybrid polypeptides with enhanced pharmacokinetic properties (2003-12-02),
9. 6623741 - Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission (2003-09-23),
10. 6562787 - Hybrid polypeptides with enhanced pharmacokinetic properties (2003-05-13),
11. 6518013 - Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission (2003-02-11),
12. 6479055 - Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission (2002-11-12),
13. 6475491 - Treatment of HIV and other viral infections using combinatorial therapy (2002-11-05),
14. 6440656 - Methods for the inhibition of respiratory syncytial virus transmission (2002-08-27),
15. 6348568 - Hybrid polypeptides with enhanced pharmacokinetic properties (2002-02-19),

Title: Dennis Michael Lambert: Innovator in Viral Inhibition

Introduction

Dennis Michael Lambert, based in Cary, NC, is a distinguished inventor with a notable portfolio encompassing 22 patents. His work primarily focuses on the development of innovative peptides with significant antiviral properties, particularly against human immunodeficiency virus (HIV) and hepatitis B virus (HepB).

Latest Patents

Some of Lambert's latest patents include isolated peptides derived from HIV types 1 and 2, which contain fusion inhibitory domains exhibiting potent anti-retroviral activities. One of the key innovations, the DP178 peptide, targets amino acids 638 to 673 of the HIV-1 gp41 protein. This invention also describes various fragments, analogs, and homologs of DP178, emphasizing their use in preventing both human and non-human retroviral transmission to uninfected cells. Another significant patent outlines methods using peptides homologous to DP-178 and DP-107 for inhibiting Hepatitis B virus transmission to uninfected cells, demonstrating their dual utility in the realm of viral infections.

Career Highlights

Throughout his career, Dennis Lambert has worked with prominent organizations, including Trimeris, Inc. and Duke University. His contributions in these settings have significantly advanced the field of virology, particularly in the area of therapeutic developments aimed at viral infections.

Collaborations

Lambert's innovative journey has been enriched by collaborations with notable colleagues such as Shawn O'Lin Barney and Stephen Robert Petteway. These partnerships have fostered a dynamic exchange of ideas and facilitated groundbreaking research in peptide technology and antiviral therapies.

Conclusion

Dennis Michael Lambert's work exemplifies the crucial intersection of innovative science and practical application in the fight against viral diseases. His patents reflect a commitment to enhancing therapeutic options and advancing our understanding of viral inhibition mechanisms. As he continues to contribute to scientific advancements, Lambert's inventions pave the way for new treatments that could potentially transform the landscape of antiviral medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…